Wall Street analysts predict that Iqvia Holdings Inc (NYSE:IQV) will post earnings of $1.47 per share for the current quarter, Zacks reports. Eleven analysts have provided estimates for Iqvia’s earnings, with estimates ranging from $1.45 to $1.51. Iqvia posted earnings of $1.40 per share during the same quarter last year, which would suggest a positive year-over-year growth rate of 5%. The business is scheduled to announce its next quarterly earnings results on Wednesday, February 13th.

According to Zacks, analysts expect that Iqvia will report full year earnings of $5.52 per share for the current fiscal year, with EPS estimates ranging from $5.50 to $5.56. For the next fiscal year, analysts forecast that the firm will post earnings of $6.26 per share, with EPS estimates ranging from $6.11 to $6.33. Zacks Investment Research’s earnings per share averages are a mean average based on a survey of research firms that follow Iqvia.

Iqvia (NYSE:IQV) last released its quarterly earnings data on Monday, October 22nd. The medical research company reported $1.42 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.39 by $0.03. Iqvia had a return on equity of 13.69% and a net margin of 12.29%. The business had revenue of $2.59 billion for the quarter, compared to analyst estimates of $2.58 billion. The business’s quarterly revenue was up 5.2% on a year-over-year basis.

A number of research analysts have recently issued reports on the company. Piper Jaffray Companies increased their target price on Iqvia to $131.00 and gave the company a “neutral” rating in a research report on Tuesday, October 23rd. Wells Fargo & Co increased their target price on Iqvia from $120.00 to $140.00 and gave the company an “outperform” rating in a research report on Monday, August 13th. Argus set a $136.00 target price on Iqvia and gave the company a “buy” rating in a research report on Thursday, August 23rd. Zacks Investment Research upgraded Iqvia from a “hold” rating to a “buy” rating and set a $142.00 target price on the stock in a research report on Tuesday, October 23rd. Finally, Morgan Stanley increased their target price on Iqvia from $130.00 to $145.00 and gave the company an “overweight” rating in a research report on Monday, December 3rd. Five equities research analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has given a strong buy rating to the company. Iqvia currently has an average rating of “Buy” and an average price target of $134.41.

In other Iqvia news, major shareholder Canada Pension Plan Investment sold 3,164,388 shares of the firm’s stock in a transaction on Tuesday, December 4th. The stock was sold at an average price of $123.72, for a total value of $391,498,083.36. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO Michael R. Mcdonnell sold 9,500 shares of the firm’s stock in a transaction on Monday, December 3rd. The shares were sold at an average price of $128.35, for a total value of $1,219,325.00. The disclosure for this sale can be found here. Insiders sold a total of 7,117,903 shares of company stock worth $881,082,166 in the last 90 days. 6.00% of the stock is currently owned by insiders.

A number of hedge funds have recently made changes to their positions in the business. Nomura Asset Management Co. Ltd. increased its stake in shares of Iqvia by 1.9% in the 3rd quarter. Nomura Asset Management Co. Ltd. now owns 25,186 shares of the medical research company’s stock worth $3,268,000 after acquiring an additional 461 shares during the last quarter. IFM Investors Pty Ltd increased its stake in shares of Iqvia by 5.4% in the 3rd quarter. IFM Investors Pty Ltd now owns 9,290 shares of the medical research company’s stock worth $1,205,000 after acquiring an additional 478 shares during the last quarter. State Treasurer State of Michigan increased its stake in shares of Iqvia by 1.0% in the 3rd quarter. State Treasurer State of Michigan now owns 48,300 shares of the medical research company’s stock worth $6,266,000 after acquiring an additional 500 shares during the last quarter. Independent Advisor Alliance increased its stake in shares of Iqvia by 4.9% in the 3rd quarter. Independent Advisor Alliance now owns 11,240 shares of the medical research company’s stock worth $1,455,000 after acquiring an additional 525 shares during the last quarter. Finally, Cleararc Capital Inc. increased its stake in shares of Iqvia by 14.7% in the 3rd quarter. Cleararc Capital Inc. now owns 4,217 shares of the medical research company’s stock worth $547,000 after acquiring an additional 540 shares during the last quarter. Institutional investors own 89.33% of the company’s stock.

Shares of NYSE:IQV opened at $117.98 on Friday. Iqvia has a 1 year low of $91.57 and a 1 year high of $135.48. The company has a market cap of $24.64 billion, a PE ratio of 27.06, a price-to-earnings-growth ratio of 1.77 and a beta of 0.81. The company has a debt-to-equity ratio of 1.41, a quick ratio of 1.09 and a current ratio of 1.09.

About Iqvia

IQVIA Holdings Inc provides integrated information and technology-enabled healthcare services in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Commercial Solutions, Research & Development Solutions, and Integrated Engagement Services. The Commercial Solutions segment offers a range of cloud-based applications and related implementation, real-world insights, and reference information services; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services.

Further Reading: What is Net Asset Value (NAV)?

Get a free copy of the Zacks research report on Iqvia (IQV)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Iqvia (NYSE:IQV)

Receive News & Ratings for Iqvia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iqvia and related companies with MarketBeat.com's FREE daily email newsletter.